

**Supplementary Table S2: Numeric results of the real time quantitative PCR before and after exposition to 5-azacytidine.** The experiments were performed with 5 donor horses in two independent repetitions. **(A)** Ct values were measured in triplets and shown as mean  $\pm$  standard deviation. **(B)** Parameter estimates (with robust standard errors) are demonstrated for OCT4/POU5F1 and MYC. For these two pluripotency markers an one-way ANOVA has been performed, as Ct mean values from T0, T3\_nc, T3\_ind were more than 4 cycles away from the mean values of NRT and H20. Afterwards, Tukey-HSD (OCT4/POU5F1) and Hochberg (MYC) post hoc tests were performed. **Abbreviations:** T0: day 0, T3: after 3 weeks, nc: negative control, ind: 5-azacytidine induction, p: positive control, NRT: non-reverse transcriptase, IRC: internal run control, GAPDH: glyceraldehyde 3 phosphate dehydrogenase.

(A)

Treatment	OCT4/POU5F1	MYC	GATA4	NKX2.5	TNNI3	MYH6	MYH7	MYF6
T0	28,26 $\pm$ 0,97	21,86 $\pm$ 0,35	32,52 $\pm$ 1,15	37,22 $\pm$ 0,71	30,83 $\pm$ 0,80	36,58 $\pm$ 1,49	34,95 $\pm$ 1,29	33,40 $\pm$ 1,57
T3-nc	29,74 $\pm$ 0,97	22,39 $\pm$ 0,62	34,14 $\pm$ 2,02	37,01 $\pm$ 0,94	32,59 $\pm$ 1,23	33,55 $\pm$ 0,49	35,53 $\pm$ 1,53	34,21 $\pm$ 1,60
T3-ind	29,59 $\pm$ 2,00	22,59 $\pm$ 1,07	33,59 $\pm$ 1,90	36,02 $\pm$ 1,91	32,32 $\pm$ 2,05	35,20 $\pm$ 1,57	34,39 $\pm$ 1,54	33,03 $\pm$ 2,31
p	28,53 $\pm$ 0,50	21,70 $\pm$ 0,30	26,83 $\pm$ 0,27	30,50 $\pm$ 0,15	16,28 $\pm$ 0,36	18,03 $\pm$ 0,20	18,65 $\pm$ 0,53	20,85 $\pm$ 0,45
NRT	34,85 $\pm$ 2,34	33,85 $\pm$ 1,71	36,70 $\pm$ 1,00	35,30 $\pm$ 0,00	32,23 $\pm$ 0,59	35,10 $\pm$ 3,53	34,70 $\pm$ 0,46	38,00 $\pm$ 4,11
H20	33,73 $\pm$ 0,90	33,77 $\pm$ 1,40	32,58 $\pm$ 2,15	37,30 $\pm$ 1,27	34,65 $\pm$ 1,50	37,80 $\pm$ 1,75	35,45 $\pm$ 0,83	34,55 $\pm$ 1,99
IRC-GAPDH	17,25 $\pm$ 0,16	17,47 $\pm$ 0,27	17,50 $\pm$ 0,30	17,42 $\pm$ 0,47	17,43 $\pm$ 0,26	17,32 $\pm$ 0,28	17,48 $\pm$ 0,17	17,25 $\pm$ 0,12

(B)

MYC

parameter estimates with robust standard errors:

dependent variable: MYC (Ct value)

parameter	regression coefficient B	p value	95% confidence interval	
			lower limit	upper limit
constant term	22,133	0	21,556	22,711
[treatment T0]	-0,373	0,218	-0,971	0,224
[treatment T3-nc]	0,107	0,76	-0,586	0,799
[treatment T3_ind]	0	.	.	.
[exp.trial=1]	0,92	0,015	0,182	1,658
[exp.trial =2]	0	.	.	.
[treatment T0] * [exp.trial=1]	-0,72	0,07	-1,5	0,06
[treatment T0] * [exp.trial=2]	0	.	.	.
[treatment T3-nc] * [exp.trial=1]	-0,613	0,163	-1,481	0,254
[treatment T3-nc] * [exp.trial=2]	0	.	.	.
[treatment T3_ind] *				
[exp.trial=1]	0	.	.	.
[treatment T3_ind] *				
[exp.trial=2]	0	.	.	.
R square = 0,283 (adjusted R square = 0,240)				

OCT4/POU5F1

parameter estimates:

dependent variable: OCT4/POU5F1 (Ct value)

parameter	regression coefficient B	p value	95% confidence interval	
			lower limit	upper limit
constant term	30,067	0	29,364	30,77
[treatment T0]	-1,66	0,001	-2,654	-0,666
[treatment T3-nc]	-0,78	0,123	-1,774	0,214
[treatment T3_ind]	0	.	.	.
[exp.trial=1]	-0,953	0,06	-1,948	0,041
[exp.trial =2]	0	.	.	.
[treatment T0] * [exp.trial=1]	0,653	0,358	-0,753	2,06
[treatment T0] * [exp.trial=2]	0	.	.	.
[treatment T3-nc] * [exp.trial=1]	1,86	0,01	0,454	3,266
[treatment T3-nc] * [exp.trial=2]	0	.	.	.
[treatment T3_ind] *				
[exp.trial=1]	0	.	.	.
[treatment T3_ind] *				
[exp.trial=2]	0	.	.	.
R square = 0,254 (adjusted R square = 0,210)				